Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology company founded in 1988 and based in Westchester County, New York. The company focuses on developing new medicines for serious medical conditions through strong scientific research and innovative technology. Regeneron has evolved into a fully integrated biopharmaceutical entity, with capabilities in research, development, manufacturing, and commercialization.

The company conducts extensive biomedical research, particularly in understanding disease biology related to cytokine and tyrosine kinase receptors. Regeneron operates its own manufacturing facilities to support clinical and commercial product supply. Its product portfolio includes several important therapies, such as EYLEA for eye diseases, ARCALYST for rare inflammatory conditions, and Dupixent for inflammatory diseases. Regeneron has also developed REGEN-COV, a monoclonal antibody cocktail for COVID-19 treatment, showcasing its ability to respond quickly to health crises.

Strategic collaborations, particularly with Sanofi, enhance Regeneron's research and commercialization efforts, allowing for shared development costs and expanded market access. The company serves patients with serious and rare diseases, healthcare providers, and pharmaceutical partners globally.